Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
europe blog main
europe top stories
3
×
life sciences
national blog main
clinical trials
eli lilly
fda
indiana blog main
indiana top stories
san francisco blog main
san francisco top stories
abaloparatide
amgen
avapritinib
blueprint medicines
boehringer ingelheim
boston
boston blog main
boston top stories
cancer
cancer drugs
capmatinib
empagliflozin
europe
european commission
gastrointestinal stromal tumors
genentech
life science
medullary thyroid cancer
national
national top stories
new york blog main
new york top stories
non-small cell lung cancer
novartis
osteoporosis
pralsetinib
radius health
roche
What
approval
3
×
drug
3
×
carries
fda
address
amgen
amgen’s
approves
bid
blueprint
boehringer
cancer
certain
designed
developed
diabetes
eli
europe
european
expand
fallen
genetic
heart
ingelheim
latest
lilly
marketed
marketing
medicine
medicines
medicine’s
nod
osteoporosis
pass
patients
raise
rejects
ret
risk
short
Language
unset
Current search:
drug
×
biotech
×
approval
×
" europe top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
